Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients
Sponsor: Central Adelaide Local Health Network Incorporated
Summary
The goal of this clinical trial is to compare responses to Varicella Zoster vaccination between transplant patients on different medication regimens, and their healthy co-habitants. The main questions it aims to answer are: 1. Are there differences in vaccination immunological responses in transplant patients on different immunosuppression regimens? 2. Are there differences in vaccination immunological responses between transplant patients and their healthy co-habitants? Participants will all receive a 2-dose course of SHINGRIX recombinant Zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination.
Official title: Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients (SIR ZOSTER)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2024-03-20
Completion Date
2027-12
Last Updated
2026-04-09
Healthy Volunteers
No
Interventions
Recombinant zoster vaccine adjuvanted (SHINGRIX)
2 doses of 0.5mL recombinant zoster vaccine adjuvanted intramuscular injection at week 0 and week 8.
Locations (1)
Royal Adelaide Hospital
Adelaide, South Australia, Australia